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Syndecan-1 (SDC1) is a heparan sulfate proteoglycan (HSPG) intercalated in the cell 
membrane but also translocated to the cell nucleus in a regulated manner. SDC1 is involved 
in several malignancy-associated processes such as proliferation and migration. Altered 
SDC1 expression can induce changes along the epithelial–mesenchymal axis and it may 
influence the prognosis of cancer. 
Transforming growth factor- (TGF-)  plays a pivotal role in many cellular functions, 
including epithelial–mesenchymal transition (EMT). In the early stages of tumorigenesis 
TGF- inhibits cell growth and induces cell apoptosis, while in the later stages it promotes 
tumor growth. 
The overall aim of this thesis was to study the role of SDC1 in mesenchymal tumors and 
functions related to the presence or absence of SDC1 in the nucleus. Understanding the role 
of cell surface and nuclear SDC1 and its interactions could be of importance for the 
understanding of tumor growth, proliferation, differentiation, and migration in these tumors. 
In paper I we used fibrosarcoma cell sub-lines to study the functions of SDC1, especially the 
molecular targets and signaling pathways regulated by its nuclear translocation. The TGF- 
pathway was activated by nuclear SDC1, and three genes were altered with the deletion of 
nuclear localization signal: EGR-1, NEK11 and DOCK8. The study shows the importance of 
the localization of SDC1 for its effect on tumor cells. The aim of paper II was to further 
study the role of nuclear SDC1 through characterizing its nuclear interactome, using a 
mesothelioma cell line. SDC1 was immunoprecipitated to identify co-precipitating interacting 
proteins. The results indicate a previously unknown role for SDC1 in RNA biogenesis. In 
Paper III we investigated if SDC1 plays a role in regulating TGF--induced EMT. The 
knockdown of SDC1 in a carcinoma cell line resulted in decreased expression of E-cadherin, 
and increased expression of N-cadherin. In fibrosarcoma cells, with its low basic SDC1 
levels, overexpression of SDC1 was sufficient to repress N-cadherin and vimentin. The 
results indicate that SDC1 regulates epithelial-mesenchymal plasticity in tumor cells. 
Together, these studies provide new insights into the role of SDC1 in tumors and the 
functional importance of the transport of SDC1 to the nucleus, as well as the connection 
between SDC1 and TGF-.  
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Cancer is characterized by the uncontrolled growth of cells, which can spread and metastasize 
to distant parts of the body. According to World Health Organization (WHO), about 9.6 
million people die of cancer each year, which is about 16 % of all deaths worldwide. The 
most common types of cancer in men are lung, prostate, colorectal, stomach and liver cancer, 
while breast, colorectal, lung, cervical and thyroid cancer are the most common among 
women. (https://www.who.int/health-topics/cancer/).  
Cancer is a group of lethal conditions where genetic damages have caused loss of functions 
that regulate the growth of the original tissue. As normal cells evolve into tumor cells, they 
acquire capabilities which enable them to evade normal cell proliferation and homeostasis. 
Those capabilities include supporting proliferative signaling, evading growth suppressors, 
resisting apoptosis, enabling unlimited replication, inducing angiogenesis, and activating 
invasion and metastasis. Other possible characteristics are the abilities to deregulate energy 
metabolism and to evade immune destruction [1]. 
As the cancer cells invade and spread to form metastasis, they change their phenotype in a 
process called Epithelial to Mesenchymal Transition (EMT). The result is a more motile and 
proliferative cell that can enter channels for spreading, such as the lymphatics, veins, and 
serous cavities. Once settled down or trapped at the metastatic site, a reversed process (MET) 
will regain its original and more epithelioid tumor phenotype, the appearance of the resulting 
metastasis being similar to the original tumor. 
1.1 SYNDECANS (SDCS) 
Proteoglycans (PGs) are proteins that carry glycosaminoglycan (GAG) side chains which are 
covalently bound to the core protein [2]. They can be classified by their location, their 
different sizes as well as the nature of their glycosaminoglycan chains. PGs are either found 
on or in the cell or in the extracellular matrix (ECM) [3]. 
The first molecule identified as an integral membrane proteoglycan was named syndecan 
(SDC) from the Greek word syndein meaning “to bind together” [4]. The SDCs constitute a 
family of four type I transmembrane heparan sulfate proteoglycans (HSPGs), which are 
located in the plasma membrane as a link between intracellular and extracellular surroundings 
[4, 5]. One central function of SDCs seems to be to regulate the ligand-dependent activation 
of primary signaling receptors at the cell surface [6]. They interact with extra-cellular ligands 
and are implicated in cellular signal transduction, which means that they are involved in 
many cellular processes [7], including cell proliferation, differentiation, adhesion, and 
migration [8]. 
SDCs are mainly localized on the cell surface but can also be released through sheddases or 
accumulate in the cell nucleus, in the tumor stroma, and in body fluids. Through shedding of 
the ectodomain, the cell-bound SDC is changed into a soluble active ligand [9]. SDC1 is 
common in epithelial cells, while SDC2 is mainly found on mesenchymal cells, SDC3 in 
neuronal tissue and cartilage, and SDC4 in all types of cells  [4, 5, 10–13]. The SDC proteins 
has three domains: a N-terminal ectodomain, a transmembrane domain and a C-terminal 
cytoplasmic domain [14]. 
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1.1.1 Core proteins 
Extracellular domain (Ectodomain)  
The N-terminal extracellular domain carries glycosaminoglycan (GAG) chains (Figure 1): 
heparan sulfate (HS) and chondroitin sulfate (CS) [14]. Through the HS chains the 
ectodomain interacts with many types of ligands in the extracellular matrix, for example 
growth factors, chemokines, collagens, cytokines, and proteinases [15], while the function of 
the CS chain is still less clarified. During angiogenesis SDC1 binds to both αv3 and αv5 
integrins via the ectodomain, while during reepithelialization of lung tissue it binds to αv1 
integrin. This leads to formation of ternary complexes between extracellular molecules, a cell 
surface receptor and a PG, like the ones associated with growth factors, their receptors and 
HS chains [16–19]. The DRKE sequence in SDC1 could possibly be essential for 
oligomerization in the same way as the EKRE motif is needed in the SDC3 ectodomain. 
However, the function of DRKE is still not clear [20]. 
 
  
Figure 1. Schematic illustration of structurally related SDC family [21]. 
Transmembrane and Cytoplasmic domains  
The single-pass transmembrane domain is highly conserved in the four SDC family members 
(Figure 2). Each SDC gene contains the GxxxG motif, which gives rise to dimers formation 
[22]. The cytoplasmic domain of SDC1 connects with several cytosolic proteins and plays an 
important role in endocytosis. It has two conserved C1 and C2 sites on each side of the 
variable region V, which is unique for each SDC family member. The C1 site mediates SDC 
dimerization and interacts with several intracellular proteins which regulate the organization 
of the cytoskeleton, for example tubulin, ezrin and cortacin [22, 23]. The RMKKK motif is 





TM: transmembrane domain 
CD: cytoplasmic domain 
Figure 2. Conserved amino acid sequences of the SDC family [25].  
1.1.2 Glycosaminoglycan (GAG) chains 
The extracellular domain of the SDC1 protein core has five serine residues, on which GAG 
chains can be synthesized. Three of these are located close to the distal N-terminus and the 
remaining two adjacent to the cell membrane. In the Golgi, the GAGs are synthesized on 
these serine residues as a repeating disaccharide structure after an initial linkage 
tetrasaccharide. In this way HS is formed on the three distal sites and CS on the proximal 
two. The HS and CS chain consists of repeating hexosamine-uronic acid disaccharides with a 
basic structure of N-acetylglucosamine-glucuronic acid in HS and N-acetylgalactosamine-
glucuronic acid in CS. Following synthesis, this basic structure can be modified by 
deacetylation, uronic acid epimerization and sulfation, which particularly in HS may result in 
a considerable structural heterogeneity, which seems to be important for different HS 
interactions [26]. In addition, several post-synthetic changes can occur also at the cell surface: 
fragmentation of HS by heparanase, selective removal of 6-O sulfate by extracellular 
endosulfatases and shedding of the entire extracellular domains by sheddases [27, 28]. The 
fragments which are generated through the selective removal of 6-O sulfate are biologically 
more active in basic fibroblast growth factor (FGF-2) signaling than the original HS chains 
[29]. 
The role of CS in the function of SDC1 is not yet well known. The presence of CS chains on 
the ectodomain close to the plasma membrane could have an effect on the ability of SDC1 to 
connect with other transmembrane receptors, change its inclination to cleavage and shedding 
by proteases, or hamper its clustering [30]. 
1.1.3 Functional interactions 
SDC1 is involved in a large range of biological functions. Changes in SDC1 can influence 
tumor phenotypes due to alterations in cell proliferation and cell growth, cell survival, cell 
invasion, metastasis, and angiogenesis [31–33]. The GAG chains bind various protein 
ligands, depending on their fine structure and position on the core protein. Since they carry 




SDC1 employs its functions mainly through the HS chain, binding several different 
morphogens and growth factors with varying affinity to high and low sulfated regions [6, 34]. 
(Table 1), For example, it binds fibroblast growth factors (FGFs), vascular endothelial growth 
factor (VEGF), Wnt, hepatocyte growth factor (HGF), and their receptors. It thereby helps to 
stabilize the growth factor/growth factor receptor complexes [35–38]. 
Table 1. Selected HS-binding ligands 
Growth factors, Growth factor receptors 
 




Fibronectin, Laminin, Collagens, 
Thrombosponin, Tenascin 
 
Cell-cell adhesion molecules 
 
L-selectin, N-CAM. PECAM, Mac-1 
The selection is partly based on Carey et al.[6]. 
Because of their fine structure, HS chains have been shown to affect the signals imposed on 
the cell by the growth factor. The HS chains on SDC1, rather than the ectodomain of the core 
protein, mediate the paracrine fibroblast growth factor 2 (FGF-2)-dependent signaling to 
stimulate growth in stromal fibroblasts of breast carcinomas [38]. On the other hand, CS 
chains also bind to matrix proteins and soluble molecules [39]. Separate domains of the core 
proteins can also bind or relate to ECM components, cell surface and cytoplasmic ligands, 
thereby modulating various cellular processes (Figure 3).  
Through an indirect interaction with 1 integrin, the ectodomains of SDC2 and -4 promote 
mesenchymal cell adhesion [40]. A similar property of a stretch of 5 hydrophobic amino 
acids -222 AVAAV226- in the ectodomains close to the plasma membrane is critical for SDC1-
mediated inhibition of cell invasion [41]. 
On their own, the transmembrane and cytoplasmic domains of SDCs do not have intrinsic 
kinase or catalytic activity, but through multimerization or interaction with different 
intracellular components like GTPases or kinases, they are essential in generating the signal 
transduction [42].  
The SDC core proteins could be brought closer together through oligomerization, which 
enlarges their interaction surfaces and thereby increases the probability of binding to other 
membrane proteins [43]. This oligomerization is crucial for triggering the cytoplasmic 
domain for downstream signaling [44, 45]. 
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The cytoplasmic region influences the actin cytoskeleton and membrane trafficking through 
binding cytoskeletal and PDZ-domain proteins. This controls SDC recycling through 
endosomal compartments, promotes internalization of accompanying proteins and regulates 
cell adhesion as well as different signaling systems [46]. 
The C-terminal EFYA domain of C2 binds to PDZ-binding proteins, for example synbindin, 
synectin, CASK [47], CASK/LIN-2 and syntenin. Syntenin is essential for vesicular 
transportation, neuronal migration, synaptic signaling, adhesion, and metastasis formation 
[48, 49]. The cytoplasmic domain of SDC1 also interacts with 6 4 integrin and through this 
regulates activation of ErbB2 [50].  
 
ED: ectodomain 
TM: transmembrane domain 
Figure 3. The structure of SDC1, showing the localization of certain peptide sequences or 
domains with corresponding ligand interactions or functions [25].  
1.1.4 Cellular distribution and nuclear localization 
In adult tissues, SDC1 is the major SDC on the basolateral surface of epithelial cells. During 
embryogenesis development, it is transiently expressed by mesenchymal cells [4].  SDC1 is 
expressed by most epithelial cells, where it supports adhesion and regulates the biological 
activity of HS-binding growth factors [51]. 
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Traditionally, SDCs are considered to function on the cell surface, but a substantial amount of 
SDC1 has been detected also in the nucleus [52]. More recent findings indicate that the 
functions of SDCs relate not only to its presence on the cell surface but also in the cytoplasm 
and nucleus. By using confocal laser microscopy to study the subcellular distribution, the 
nuclear translocation of SDC1 was shown to be time- and tubulin dependent. Following 
seeding of the mesothelioma cells, SDC1 is first present in the cytoplasm and then in the 
nucleus. Only later it can be seen in the cell membrane, often at contact sites between cells. 
The nuclear translocation of SDC1 takes place in a time- and tubulin-dependent manner. This 
has been shown in different types of carcinomas, in neuroblastoma and in benign mesothelial 
and endothelial cells [52]. Interference with tubulin integrity will inhibit the transport of 
SDC1 to the nucleus [52] and affect cell proliferation. Our recent study also shows that SDC1 
plays a part in the formation and export of RNA (Paper II). SDC1 can be found inside the 
cell nuclei of several types of cancers. It has been found in the nucleus of mesothelioma, 
adenocarcinoma, breast cancer, hepatocellular carcinoma, neuroblastoma and myeloma cells 
[52–54]. 
Various studies of the presence of PGs and GAGs in the nucleus show that they play a role in 
the control of cell division, the transportation of FGF-2 into the nucleus [55]  and suppression 
of DNA topoisomerase I activity [56]. 
The minimal structural requirement for the nuclear translocation of SDC1 is the conserved 
juxta-membrance RMKKK motif, which works as a nuclear localization signal (NLS), 
essential for tubulin-dependent nuclear translocation of SDC1 [53]. Substitution of the 
arginine in the RMKKK sequence decreases in the proportion of cells with nuclear SDC1 
considerably, indicating the central role of arginine in this nuclear translocation. Removal of 
this highly conserved sequence prevents the nuclear translocation of SDC1. The MKKK 
sequence is also involved in raft-dependent endocytosis [24]. 
Questions that remain to be answered are for example, which molecules accompany them 
along the way and the role they play in the nucleus. Since SDC1 has been found in the 
nucleus [52], it could possibly function as a transcription factor and impact gene regulation 
affecting cancer pathogeneses.  
It has been shown that loss of SDC1 from the nucleus of myeloma cells results in increased 
histone acetyltransferase (HAT) activity as well as increased expression of genes driving 
tumor progression [57]. However, we are only at the beginning of understanding the route 
and functional significance of this nuclear transport.  
It has recently been found that also shed SDC1 may translocate to the nucleus of both tumor 
cells and bone-marrow-derived stromal cells [57]. An important factor regulating the level of 
both HS and SDC1 in the nucleus is heparanase, an endoglycosidase that cleaves HS and 
causes a considerable decrease in nuclear SDC1 levels in a concentration-dependent manner. 
This implies that HS chains are of importance for the nuclear translocation or degradation of 
SDC1. In many types of cancer, overexpression of heparanase is related to poor prognosis 
[58]. Depending on the concentration, overexpression, or addition of heparanase, this reduces 
the amount of SDC1 in the nucleus of myeloma cells. This indicates that also HS chains are 
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important for the nuclear translocation of SDC1 [54]. In malignant mesothelioma cells TGF-
 inhibits the nuclear translocation of SDC1, with an antiproliferative effect as result [59]. 
1.1.5 Ectodomain shedding 
Shedding is a process in which the SDC ectodomains are released from the surface of the cell 
by endogenous proteolytic cleavage [60]. One of the cleavage sites is G245-L246, which is 
placed about 7 amino acids from the cell membrane in human SDC1 [61]. During shedding 
SDC is converted from receptors on the membrane to soluble HSPG effectors, which 
compete with their equivalents on the cell surface in binding ligands [62]. The enzymes that 
regulate SDC1 shedding are matrix metalloproteinases (MMPs), including MMP-7, MMP-9, 
membrane-bound metalloproteinases (MT-MMP1) as well as disintegrin and 
metalloproteases (ADAM10, ADAM17) [61, 63–66]. Also, heparanase has been found to 
accelerate MMP-9 mediated shedding of SDC1 [35]. SDC1 expression is actually known to 
suppress the level of MMP-9 and inhibit cell invasion into type I collagen [67, 68]. However, 
the process of shedding is not yet fully known [69]. 
Patophysiological disorders, like tissue injury and inflammation [63, 70]  or cancer forms like 
multiple myeloma [71], lung cancer [72] and Hodgkin’s lymphoma [73], can cause 
acceleration in SDC shedding. Accelerated shedding can also be generated by physiological 
stimuli, such as chemokines, bacteria, growth factors, and cellular stress [29]. Heparanase 
increase SDC1 shedding by stimulating protease expression, which could explain the 
stimulation of tumor growth and metastasis [74, 75]. Chemotherapy can actually activate 
shedding of SDC1, especially through ADAMs, which leads to a more aggressive and 
therapy resistant phenotype [76].  
SDC shedding has functional effects on cancer cells (Figure 4). For example, in breast cancer 
cells, SDC1 has different roles when in soluble form compared to when bound to the cell 
membrane. In adenocarcinoma cells, overexpression of SDC1 on the cell surface stimulates 
proliferation and inhibits invasion; on the other hand, overexpression of shed SDC1 has the 
opposite effect [77]. 
Soluble SDC1 also promotes growth of myeloma tumor cells, since the cells lacking its 





Figure 4. Schematic representation of the influence of SDC1 on tumor cells. SDC1 is cleaved 
by sheddases (e.g. ADAMS and MMPs), resulting in soluble SDC1 (sSDC1), which binds to 
growth factors and stimulate their signaling [33]. (Reprinted with permission of Elsevier) 
1.1.6 SDC1 in cancers 
The expression of SDC1 is related to the inhibition of tumor cell growth and invasiveness, as 
well as the maintenance of epithelial morphology, and changes in this expression can 
influence tumor cell behavior. SDC1, like other proteoglycans, affects tumorigenesis by 
altering the process of cell proliferation, apoptosis, angiogenesis etc. [79]. Suppression of 
SDC1 expression has been shown to change the tumor cell into a mesenchymal phenotype 
with loss of E-cadherin and altered cell morphology [80]. SCD1 expression also regulates cell 
differentiation in malignant mesothelioma [8, 81]. 
In several cancers, for example ovarian [82], breast [83], colorectal carcinomas [84] and 
mesothelioma [8, 85] the SDC1 expression is dysregulated and gradually lost [86]. In other 
types of human cancer SDC1 is highly expressed and in multiple myeloma it can even be 
used as a diagnostic biomarker [87]. Low SDC1 expression is correlated with a worse 
prognosis in head and neck tumors [88], as well as colorectal [89] and lung [90] cancer. In 
both lung cancer and mesothelioma, the presence of cell membrane-bound SDC1 is related to 
better prognosis [8, 90], whereas the shed soluble SDC1 correlates to worse prognosis. 
Down-regulation of SDC1 has been shown in mesenchymal tumors like human fibrosarcoma 
[91]. Low cell surface SDC1 level is associated with poor prognosis, for example in lung 
cancer. This means that SDC1 may have two different roles in different types of cancer, 
either as an inhibitor or promoter of tumor progression [85]. 
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The process through which SDC1 regulates the survival and proliferation of tumor cells is 
dependent on the cell type. Different signaling pathways are related to SDC1 as a co-receptor. 
SDC1 null mice have been found resistant against Wnt-1 induced mammary tumorigenesis, 
with SDC1 acting as a co-receptor for Wnt signaling in an HS-dependent manner [36]. 
Another pathway is the signaling of Hepatocyte growth factor (HGF) through its receptor 
Met, which is significant for cancer development [92, 93]. For example, HGF can bind HS 
chains of SDC1 in myeloma [37]. Heparanase induces SDC1 shedding in myeloma cells via 
MMP-9 upregulation [75] and increases HGF expression [94]. 
The role of shed SDC1 in the tumor stroma can conflict with the role of cell bound SDC1, 
depending on the type of cell. Stromal SDC1 enhances the proliferation of breast epithelial 
cells [95]. It is also related to a poor prognosis in oral [96], ovarian [82] and gastric 
carcinoma [97]. Ectodomain shedding of SDC1 from stromal fibroblasts enhances tumor cell 
growth by activating FGF2 signaling [38]. In mammary tumor cells SDC1 overexpression in 
fibroblasts also leads to increased cancer cell proliferation [98]. This means that stromal 
SDC1 can save and dispense heparin-binding growth factors such as EGFs, FGFs and HGF to 
stimulate cancer cell proliferation [86]. 
SDC1 regulates tumor cell apoptosis in different ways depending on cell type. In myeloma 
cells SDC1 silencing engenders apoptosis [99], which could be caused by decreased levels of 
cell surface SDC1 as co-receptors for growth factor signaling. On the other hand, in MCF-7 
breast cancer cells the reverse effect has been shown, when apoptosis was enhanced by 
adding human recombinant SDC1 ectodomain [100]. The varying effect that SDC1 can have 
on growth and apoptosis in different tumor cells, could partly be explained by their different 
requirements for growth factors. Also, each tumor has a unique microenvironment and SDC1 
HS chains could be modified, with the effect of either stimulating or inhibiting tumor cell 
growth and apoptosis [101]. The opposing functions of SDC1 in tumor cell apoptosis may 
also be caused by the bell-shaped activity curve of HS in regulating HS-binding ligands [86]. 
HS can bring the ligand and its binding partner closer together and facilitates the interaction 
by increasing the local concentration of the ligand. Depending on whether HS-binding is 
inhibiting or stimulating the ligand, the bell-shaped curve may be concave or convex [86]. 
Integrins are essential receptors in cell adhesion, proliferation, and migration [102]. SDC1 
can interact with αv and αv integrins and trigger their signaling through the involvement 
of αv ligands such as vitronectin, laminins, collagens, and fibronectin [16]. Also, integrins and 
SDC1 can form a link between the ECM and the cytoskeleton, stabilizing the focal adhesions, 
which inhibits cell migration and increases adhesion [86, 103]. 
Myeloma cell invasion into type I collagen gel is inhibited by SDC1 expression [68]. Within 
the SDC1 ectodomain, an invasion regulatory domain has been shown to inhibit the invasion 
of myeloma cells [41]. Overexpression of full-length SDC1, or a truncated variant without the 
ectodomain, stimulates metastasis of fibrosarcoma in a mouse model [104]. 
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It has been shown that membrane-bound and soluble SDC1 play different roles in breast 
cancer progression [77]. While cell proliferation is increased by overexpression of full-length 
SDC1, it is decreased by shed SDC1. On the other hand, membrane-bound SDC1 inhibits 
invasiveness, while shed SDC1 promotes cell invasion. This means that the SDC1 shedding 
involves a change from a proliferative to an invasive phenotype. 
1.2 MESENCHYMAL TUMORS 
The focus in this PhD study is on the role of SDC1 in malignancy and changes in phenotype 
and biological behavior, in particular the process of EMT. For this purpose, we have chosen 
two mesenchymal tumors: malignant mesothelioma (MM) and fibrosarcoma- both with low 
endogenous expression of SDC1 and for comparison a cell line with high expression level 
(Paper III). Both these tumors often have biphasic growth, i.e., they may have simultaneous 
presence of both epitheliod and sarcomatoid characteristics [105]. They can undergo a 
reversible morphological transition between these two phenotypes, which facilitates the study 
of how cell differentiation and tumor progression are regulated. 
1.2.1 Malignant Mesothelioma (MM) 
MM begins as a localized tumor, but it spreads rapidly along mesothelial surfaces [106]. 
Pleural MM primarily emerges from the surface serosal cells or the fibroblast like mesothelial 
cells just beneath the surface of the pleura [107]. As the MM cells infiltrate the pleura, they 
cause the formation of an effusion. This leads to difficulties to breathe due to reduced space 
for lung expansion [108]. Because of lack of early symptoms, MM is usually diagnosed at an 
advanced stage and the patient's life expectancy is quite short. Although MM is most 
common in the pleura, it may also appear in the other serous cavities of the body, such as in 
the peritoneum, pericardium and in the tunica vaginalis testis [109, 110]. 
Most MMs are caused by exposure to asbestos or asbestos-like minerals such as erionite 
[111, 112]. Asbestos is a carcinogenic mineral fiber, which may penetrate the pleura after 
having been inhaled. It has been suggested that the asbestos fibers interfere with the mitotic 
spindle, leading to aneuploidy [113]. A perhaps more important hypothesis is that the 
asbestos crystals, that attract iron-containing elements (hemosiderin, ferritin) to form the 
ferruginous bodies, through these iron deposits cause reactive oxygen species, that cause 
DNA damage and subsequent oncogenesis [107]. 
Asbestos has now been prohibited in Western countries, but due to the long latency for MM 
development– 20 to 50 years – of MM and the fact that asbestos is still used in other parts of 
the world, MM remains an increasing problem [109, 114, 115]. Ten percent of MM cases 
may relate to other asbestos-like materials such as erinonite or to genetic predispositions 
[116, 117]. The prognosis for this tumor is poor, the survival time being around 12 months 
after diagnosis. Mesotheliomas are often resistant to treatment, average improvement from 
chemotherapy being only a few months prolonged survival [137, 138]. 
SDC1 expression in MM is lower than in epithelial malignancies, which may suggest SDC1 
to be useful as a biomarker in MM, related to better prognosis. Epithelioid MM expresses 
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higher levels of SDC1, while the less differentiated sarcomatoid MM shows low or negative 
expression of SDC1 [8, 81]. 
In culture SDC1 overexpression in MM cells inhibits tumor growth [120] and migration, and 
enhances cell adhesion [24]. Downregulation of SDC1 leads to a more sarcomatoid 
phenotype, and a decreased level of SDC1 on these cells indicates EMT transition, which 
would correspond to worse prognosis [81]. 
1.2.2 Fibrosarcoma 
Fibrosarcoma is a somewhat less common malignant tumor that may relate to exposure to 
radiation [121]. This tumor expresses different GAGs and PGs [122]. The level of SDC1 is 
usually low but some cell lines can still express this PG [91, 120]. The location seems to be 
crucial for the effect of SDC1 on fibrosarcoma cells. While cell membrane bound SDC1 
inhibits migration on collagen, migration is enhanced by membrane type I metalloprotease 
(MT1-MMP) mediated shedding [61]. 
Fibrosarcoma cells with an overexpression of SDC1 have higher growth rates and develop 
more lung metastases [104]. However, SDC1 overexpression has different effects depending 
on type of fibrosarcoma cells. The proliferation and migration of sarcomatoid fibrosarcoma 
cells is inhibited [24, 120], while epithelioid fibrosarcoma cells are enhanced with SDC1 
overexpression together with SDC2 [104, 123]. 
1.3 TGF- IN CANCER 
Transforming growth factor- (TGF-) is a cytokine which maintains tissue homeostasis and 
is important during embryogenesis [124]. TGF- can be produced by the tumor cell itself or 
cells in its microenvironment, such as stromal cells, macrophages and platelets [125–127]. 
Also, secreted TGF- stored in the ECM can be released through the increase in matrix 
degradation factors associated with tumors [128–130]. 
TGF- plays a role in many cellular functions, such as cell proliferation, differentiation, and 
control of apoptosis. It hampers the proliferation of various human cell lines and tissues, such 
as hepatocytes, thyroid, mammary and colon epithelial cells [131]. In cancer cells, TGF- 
cannot induce changes in myc, ID-1, and ID-2 because of somatic mutations in parts of the 
TGF- signaling pathway [131, 132]. It has been shown that TGF- produced by tumor cells 
acts on itself in an autocrine manner to stimulate the suppression of tumors. Some studies 
indicate that TGF-RI and TGF-RII are genes that inhibit tumor growth. Ovarian, cervical, 
gastric, head and neck carcinomas can be related to mutations in TGF-RI and TGF-RII 
[133]. TGF-RIII is expressed in epithelial cells and can suppress cancer progression. On the 
other hand, loss of TGF-RIII is associated with disease progression and poor prognosis 
[131, 132, 134]. 
TGF- also participates in EMT [135–138]. It regulates cellular microenvironment and 
prevents tissues from becoming malignant [139]. Paradoxically, TGF- also promotes cell 
migration, invasion, and metastasis, mainly through induction of EMT [140]. It can also 
promote the colonization of the malignant cells to form metastases through the reversed 
mesenchymal-to-epithelial transition (MET) and up-regulation of metastatic niche genes. 
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When breast cancer cells metastasize to the lung, TGF- promotes MET via an ID1-Twist1 
signaling axis [141]. In this way, TGF- plays dual roles in cancer (Figure 5). In the early 
stages of tumorigenesis TGF- inhibits cell growth and induces cell apoptosis, while in the 
later stages it promotes tumor growth. As the tumor cells undergo EMT their growth is no 
longer inhibited by TGF-, which instead supports invasion and metastasis [142]. Studies 
have shown a resemblance  between MM and EMT, indicating that the three mesothelioma 
phenotypes (epithelioid, sarcomatoid and biphasic) could be an illustration of the EMT axis 
[143, 144]. In epithelioid to sarcomatoid mesothelioma tissues, a change from epithelial to 
mesenchymal markers can be seen moving towards EMT (e.g. loss of E-cadherin and 
increase in N-cadherin and vimentin) [144]. Although mesothelioma can express both E-
cadherin and N-cadherin, the mesothelial marker NCAM is central in both phenotypes [145] 
and Vimentin is often expressed in epithelioid mesotheliomas [146]. 
Although TGF- can suppress cancer initiation, in cancer that do develop there has been 
noted an increased expression of TGF- ligands in breast [147, 148], lung [149], colorectal 
[150], and pancreatic cancers [151]. In these cancers, higher TGF- ligand levels have been 
shown locally and systemically, with increased levels in the circulation. In lymph node 
metastasis, a higher level of TGF- has been demonstrated, compared with primary tumors or 
in tumors that eventually metastasize [147, 149–154]. 
 
Figure 5. TGF- has a dual role in cancer as a tumor suppressor and promoter, controlling 
proliferation, apoptosis and EMT [155]. (Reprinted with permission of Portland press) 
 
1.3.1 TGF--induced EMT  
During malignant transformation, cancer progression and metastasis, normal epithelial cells 
go through molecular and morphological changes, which give them mesenchymal 
characteristics and a migratory phenotype (Figure 6). The transcriptional repression of 
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epithelial markers is one of the first essential stages in this epithelial-mesenchymal transition 
(EMT) [156, 157], which results in loss of E-cadherin and SDC1 [80, 158]. SDC1 is 
necessary to maintain the epithelial phenotype. EMT can be induced in various cell types 
through TGF-, which plays an essential role in the activation of various EMT inducing 
transcription factors [157]. For a complete EMT, cooperation between TGF- and other 
pathways, such as Ras, is necessary [159–162]. SMAD signaling is also necessary for TGF-
-induced EMT [161]. The binding of TGF- to its receptors leads to phosphorylation of 
SMAD2/3, partnering with SMAD4 and translocating to the nucleus where the expression of 
target genes is controlled by SMAD transcriptional complexes. Cells read TGF- signals 
differently and the range of SMAD cofactors active at the time affects the outcome of the 
response [162]. SMAD complexes could either stimulate activation or repression of target 
genes, depending on the cofactors present. It has been shown that several transcription factors 
promoting EMT, such as Snail, Zeb1 and Zeb2, can act as SMAD cofactors. The interaction 
of SMAD with these transcription factors generates EMT-promoting SMAD complexes 
[163]. 
 
Figure 6. During EMT epithelial cells transform step by step from an epithelial to a 
mesenchymal phenotype [157]. (Reprinted with permission of American Society for Clinical 
Investigation) 
TGF- induces EMT either through canonical or non-canonical pathways. TGF-β promotes 
cytoskeleton reorganization by inducing focal adhesion kinase signaling, smooth muscle actin 
expression and stress fiber formation [164]. These EMT-associated changes make cells lose 
their connection to other epithelial cells, obtain a fibroblast phenotype, and migrate from their 
initial location, promoting cancer metastasis. 
The gene expression analysis of tumor-propagating breast cancer cell populations expressing 
the cell surface markers CD44+/CD24low indicates a role of TGF-β-induced EMT in human 
cancer. Cancer cells from different patients showed a common gene expression pattern, 
which suggests the presence of an active TGF-β pathway [165].  
The TGF-β signaling pathway is very important in metazoan biology, and its misregulation 
can result in tumor development. It also modulates processes such as cell invasion, immune 
regulation, and microenvironment modification that cancer cells can use to their advantage 
[139]. There is a regulatory mechanism in which TGF-, and the SDC1 cytoplasmic domain 
coordinate to induce cell surface expression of SDC1 in epithelial cells [166].   
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The differentiation of mesothelioma is dependent on the expression of SDC1 on the cell. The 
SDC1 level is usually low in mesenchymal cells, but during embryonal morphogenesis it 
increases [167–171]. At the same time, there is a loss of SDC1 in the adjacent epithelium. 
This low level of SDC1 in mesenchymal tumors is the reason why the expression and 
function SDC1 is less studied than in carcinomas. 
SDC1 is the principal SDC of epithelial malignancies, while in mesenchymal tumors its cell 
surface expression level is normally low, but its expression is related to epithelioid 
differentiation. On the other hand, loss of cell surface SDC1 expression correlates with 




2 AIM OF THE STUDY 
The overall aim of this thesis was to study the role of SDC1 in mesenchymal tumors and the 
functional importance of the transport of SDC1 to the nucleus. Particular attention is paid to 
what effects can be associated with tumor cell proliferation. Deeper knowledge of the role of 
cell surface and nuclear SDC1 and its interactions might make it possible to control tumor 
growth, proliferation, differentiation, and migration in these tumors. Such knowledge may be 
of fundamental importance in case SDC1 functions can be targeted in a therapeutic context. 
2.1 SPECIFIC AIMS 
➢ Paper I: To study the downstream effects of cell surface and nuclear SDC1 
➢ Paper II: To study the role of SDC1 by characterizing its nuclear interactome in a 
mesothelioma cell line 






3.1 SDC1 CONSTRUCTS 
To separately study the role of the cell surface and nuclear SDC1 two constructs had been 
designed: a full-length SDC1 and a truncated variant lacking the RMKKK nuclear 
localization signal (NLS) [24]. The deletion of the RMKKK sequence makes it possible to 
dissect functions related to the cell surface and nuclear SDC1, respectively. Mesenchymal 
cells were transfected with the constructs above. To obtain stable transfectants, cells carrying 
the integrated plasmid had been selected by the antibiotic geneticin. Verification of SDC1 
expression on RNA and protein level was performed by quantitative reverse transcriptase 
polymerase chain reaction (qRT-PCR). Both membrane and intracellular SDC1 were also 
detected by fluorescence-activated cell sorting (FACS) analysis or fluorescence microscopy. 
3.2 CELL LINES 
To study mesenchymal-epithelial transdifferentiation, we compare well-established 
mesothelioma and fibrosarcoma cell lines, which grow with epithelioid or sarcomatoid 
phenotypes, were compared. Both cell lines have mesenchymal origin and are selected based 
on their low endogenous SDC1 expression, providing the opportunity to study effects of 
added SDC1.  
For the study of Paper I, human fibrosarcoma cell line B6FS [173] was used. This cell line 
can differentiate into either an epithelioid or a fibroblast-like phenotype. Paper II is based on 
the mesothelioma cell line STAV-AB, originally established from a pleural effusion [174]. 
When grown in human AB-serum, this cell line has a predominantly epithelioid morphology 
[81]. Both these cell lines have a comparatively low basic expression of SDC1. In Paper III 
the B6FS cell line was compared to a human lung adenocarcinoma cell line, A549, obtained 
from American Type Culture Collection (ATCC). 
These mesenchymal tumor cell lines were used for transfection of the different constructs. 
Stable transfections were achieved in both STAV-AB and B6FS cell lines by geneticin 
selection; the B6FS transfectants were further selected by FACS. 
3.3 LABORATORY ASSAYS 
3.3.1 Fluorescence Activated Cell Sorting (FACS) 
This method was used to validate SDC1 overexpression in Papers I, II, and III. The 
technique allows the identification of various parameters of single cells, physical properties 
like size and granularity, as well as specific fluorescent antibody labels. 
3.3.2 Gene silencing 
Transient silencing of SDC1 (Papers II, and III) was performed using siRNA constructs for 
the corresponding gene [175]. Scrambled siRNA sequences were used as negative control. 
Silencing was validated on mRNA and/or protein level using qPCR and/or western blot. The 
benefit of using siRNA silencing is that the effect is achieved after only a couple of days. 
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3.3.3 RT-qPCR and Western Blot 
Quantitative reverse transcriptase polymerase chain reaction (RT-qPCR) was used for the 
gene expression (Paper I and Paper II). RT-qPCR was performed with the Platinum 
SybrGreen qPCR SuperMix-UDG kit (Invitrogen) and DNA-polymerase, with a set of 
sense/antisense primers (CyberGene AB, Sweden). 
The primers were designed based on gene sequences from GeneBank (NCBI), except for 
GAPDH [176] and SDC1 [87]. All PCR reactions were performed with an iCycler machine 
(CFX96TM Real Time PCR Detection System, BioRAD Hercules, CA, USA). The 
analyses were performed with Bio-Rad CFX Manager Software 2.0 (BioRad Laboratories 
2008). Data were analyzed with the 2-ΔΔCt method. Each target was normalized to GAPDH, 
as the reference gene, and the fold-change in expression was measured for each target with 
respect to the corresponding controls.  
Western blotting was used to demonstrate expression of different proteins (Papers I, II and 
III), using HRP-conjugated secondary antibodies together with the more sensitive Odyssey 
Imaging System (LI-COR). To compare the expression of the protein in question, a stable 
loading control GAPDH was used.  
3.3.4 Immunoprecipitation  
Immunoprecipitation (IP) was used to isolate specific proteins with their interacting partners. 
This technique is used in Paper II. After confirming the presence of SDC1 in the sample by 
Western blotting, the immunoprecipitates were subjected to proteomic screening using mass 
spectrometry for the identification of interacting partners of SDC1. 
3.3.5 Proteomic analysis 
In Paper I isoelectric focusing was used to fractionate our Tandem Mass Tag (TMT) 10-
plexes, to reduce the complexity of the proteome. The recently developed, high resolution, 
isoelectric focusing method (HiRIEF [177]), with an immobilized pH gradient of 3.7 to 4.9 
(provided by GE healthcare, Uppsala, Sweden), was applied. The fractions were then injected 
separately on a Q Exactive mass spectrometer. This procedure has been described earlier in 
more detail [177]. 
The proteomic screening was performed at the Karolinska Bioinformatic Center (Paper II). 
On-bead reduction, alkylation and digestion (trypsin, sequencing grade modified, Pierce) 
were performed followed by SP3 peptide clean-up of the resulting supernatant [178]. Each 
sample was separated and analyzed using a Thermo Scientific Dionex nano LC-system in a 3 
hr 5-40 % ACN gradient coupled to Thermo Scientific High Field QExactive. The software 
Proteome Discoverer (vs.1.4) including Sequest-Percolator for improved identification was 
used to search the Homo sapiens Uniprot database for protein identification, keeping false 




3.3.6 Bioinformatic analysis 
In Paper I a differential gene expression analysis was performed, based on Affymetrix data, 
with OCplus package provided in R software (http://www.R-project.org/). For each pair of 
data, the functional analysis on the previously established, differentially expressed genes was 
applied. In addition to a differential analysis of the fold-change, a global network analysis of 
functional coupling was performed to reveal the involvement of genes with specific 
biological functions, which were apparent when SDC1 was overexpressed with or without 
NLS. This allowed investigation of functional relationships between differentially expressed 
genes and highlighted differentially expressed genes that might be direct binding partners of 
SDC1. 
We used two approaches for identifying the sub-cellular compartments of the SDC1 
interacting proteins (Paper II). First, already known sub-cellular locations of the human 
proteins were extracted from the Human Protein Atlas database and after matching the 
protein IDs/names, the sub-cellular localization was assigned to these proteins. Secondly, 
DeepLoc-1.0 tool was used to find the sub-cellular localization of the remaining proteins. 
Further, SDC1-interacting proteins were classified into different pathways using Webgastalt 
web server and KOBAS (KEGG Orthology Based Annotation System). The pathway 
analysis was performed in two steps; (1) pathways analysis of all identified interacting 
proteins; (2) pathways analysis of the nuclear proteins. Three pathways, namely Spliceosome, 
Ribosome and RNA transport, were identified as significant in these two analyses. As our 
interest was to understand the role of SDC1 in the nucleus, the nuclear proteins which interact 
with SDC1 were identified for further analysis. We selected top two proteins EWSR1 and 
FUS based on their higher average peak area values. The nuclear localization of both the 





4 SUMMARY OF PAPERS 
4.1 PAPER 1 
Molecular targets and signaling pathways regulated by nuclear translocation of 
syndecan-1 
The cell-surface heparan sulfate proteoglycan SDC1 is important for tumor cell proliferation, 
migration, and cell cycle regulation in various types of malignancies. However, recent studies 
have shown that SDC1 also translocates to the cell nucleus, where it might regulate various 
molecular functions. To dissect the functions of SDC1 related to the nucleus and separate 
them from functions related to the cell-surface, we used two fibrosarcoma cell sub-lines.  
Multiple, unsupervised global transcriptome and proteome profiling approaches were 
implemented and combined functional assays to disclose the molecular mechanisms that 
govern nuclear translocation and its related functions. Nuclear translocation of the full-length 
SDC1 hampered the proliferation of fibrosarcoma cells compared to the NLS-deleted SDC1. 
The growth inhibitory effect of nuclear SDC1 corresponded to a significant accumulation of 
cells in the G0/G1 phase, which indicated a possible G1/S phase arrest.  
Genes and pathways related to the nuclear compartment were also identified with network 
enrichment analysis of the transcriptome and proteome. The TGF-β pathway was activated by 
nuclear SDC1, and three genes were considerably altered with the deletion of nuclear 
localization signal: EGR-1 (early growth response 1), NEK11 (never-in-mitosis gene a-
related kinase 11), and DOCK8 (dedicator of cytokinesis 8). These genes were related to 
growth and cell-cycle regulation. Nuclear translocation of SDC1 influenced the activity of 
several other transcription factors, such as E2F, NFκβ, and OCT-1. The transcripts and 
proteins affected by SDC1 were very similar in their corresponding biological processes. 
These processes were dominated by protein phosphorylation and post-translation 
modifications, which suggests changes in intracellular signaling. We also identified 
molecules involved in the known functions of SDC1, including extracellular matrix 
organization and transmembrane transport. Removal of nuclear translocation of SDC1 
resulted in a set of changes clustering in distinct patterns, which shows the functional 
importance of nuclear SDC1 in hampering cell proliferation and the cell cycle. This study 
accentuates the importance of the localization of SDC1 when considering its effects on tumor 
cell fate.  
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4.2 PAPER 2 
Mapping the Interactome of the Nuclear Heparan Sulfate Proteoglycan Syndecan-1 in 
Mesothelioma Cells 
SDC1 regulates many different signaling pathways which control the proliferation and 
migration of malignant mesothelioma and other types of cancer. It has previously been shown 
that SDC1 can translocate to the nucleus in mesothelioma cells through a tubulin-dependent 
transport mechanism. The aim of this study was to gain further knowledge about the role of 
nuclear SDC1 through characterizing its nuclear interactome in a mesothelioma cell line. 
SDC1 was co-immunoprecipitated in the mesothelioma cell line to identify interacting 
proteins. The precipitates contained many different proteins, which showed the recovery of 
protein networks. Through proteomic analysis with a focus on nuclear proteins, an 
association with pathways related to cell proliferation and RNA synthesis, splicing and 
transport was revealed. The top RNA splicing candidates were verified to interact with SDC1 
by Co-IP and subsequent Western blot analysis. Further experiments examining the loss and 
gain of function revealed that SDC1 effects RNA levels in mesothelioma cells. The results 
show a proteomic map of SDC1 nuclear interactors in a mesothelioma cell line and indicate a 
previously unknown role for SDC1 in RNA biogenesis. These results could be a basis for 
further studies on the role of nuclear SDC1 in different types of normal and cancer cells.  
4.3 PAPER 3 
Regulation of epithelial-mesenchymal plasticity in tumor cells by syndecan-1 
SDC1 is a cell surface proteoglycan that also may translocate into the nucleus. In tumor cells 
this PG plays multiple roles that may relate to cancer progression. Loss of SDC1 can induce 
epithelial-mesenchymal transition (EMT), a latent developmental process, which, when 
activated in tumors, promotes tumor cell invasion, migration, and metastasis. The cytokine 
transforming growth factor beta 1 (TGF-1) is a forceful inducer of EMT and is frequently 
overexpressed in cancer tissues. Our previous study indicates a link between SDC1 and the 
TGF-1 signaling pathway.  
The aim of the present study was to investigate whether SDC1 plays a role in regulating 
TGF-1-induced EMT. To study this, we knocked down SDC1 in a cellular model of TGF-
1-induced EMT in human A549 lung adenocarcinoma cells. This resulted in decreased 
expression of E-cadherin, and increased expression of N-cadherin and nuclear staining of the 
core EMT transcription factor Zeb1 after TGF-1 exposure. Consequently, loss of SDC1 
sensitized A549 cells to TGF-1-induced EMT. Further experiments showed that 
overexpression of SDC1 was sufficient to repress N-cadherin and vimentin in B6FS 
fibrosarcoma cells. The results of this study indicate that SDC1 plays a role as a regulator of 




5 RESULTS AND DISCUSSION  
This thesis provides some new insights into the role of SDC1 in tumors and the study of the 
functional importance of the internalisation and transport of SDC1 to the nucleus, as well as the 
connection between SDC1 and TGF-. 
SDC1 plays an important role in tumor cell proliferation and migration in many types of cancer. 
Its effects are very different depending on the origin of the tumors and their tissues [24, 120, 
179–182]. In the first study we tested the functions and molecular pathways related to nuclear 
translocation of SDC1, with focus on cell growth. To investigate the functions of SDC1 in the 
nucleus and on the cell surface we used a fibrosarcoma model, with the nuclear localization 
preserved and hampered respectively [24] We mapped the molecular mechanisms governing 
these functions, through combining transcriptomic and proteomics approaches.  
Our research group has previously demonstrated that SDC1 translocates to the nucleus in a 
regulated manner [52]. Here it was shown for the first time that the nuclear translocation of 
SDC1 has anti-proliferative effects. We found that cell proliferation is inhibited after 
transfection with full length SDC1 carrying the nuclear localization signal RMKKK, as well as 
when SDC1 expression is suppressed. Also, cells with nuclear SDC1 accumulated more in the 
G0/G1 phase of the cell cycle then those with hampered nuclear localization. 
SDC1 has been found to both enhance and inhibit cell apoptosis depending on the cell type. For 
example, SDC1 inhibited apoptosis in myeloma [183], while knock-down SDC1 had the 
opposite effect in myeloma [99] and carcinoma cells [184]. In our experiments, the anti-
proliferative effect of nuclear SDC1 was combined with inhibition of apoptosis, which suggests 
that these two mechanisms might be connected.  
The subcellular localization of SDC1 generated various molecular changes, which were 
classified and analyzed through bioinformatics. Network analyses mainly showed changes in 
genes and pathways connected to the nuclear compartment. SDC1 overexpression was found to 
change cell cycle regulation and TGF- signaling pathways, which corresponds with our earlier 
data [175, 185, 186]. 
We also identified three genes that were significantly enhanced by the nuclear translocation of 
SDC1: EGR-1, NEK11 and DOCK8. EGR-1 and NEK11 are both proteins present in the 
nucleus, which play many roles in the cell cycle. EGR-1 is a transcription factor activated by 
different extracellular stimuli and apoptotic signals. It has a dual role, sometimes promoting 
tumor growth and inhibiting apoptosis, while having the opposite effect in other tumor types 
[187]. In non-small lung cancer, the TGF--induced EMT was hampered by EGR-1 [188]. In 
our study, nuclear SDC1 generated EGR-1 expression, which was related to activation of the 
TGF- pathway and hampering of apoptosis. The NEK11 protein is DNA damage-responsive, 
and its kinase activity is needed for DNA damage-induced G2/M arrest [189]. DOCK8 is a 
guanine nucleotide exchange factor, which plays a role in the regulation of cell morphology, 
intracellular signaling, tumor cell invasion [190] and metastasis [191].  
This study shows that the upregulation of SDC1 inhibits cell proliferation and that the 
localization of SDC1 might affect how tumor cells develop. The results indicate that 
transcription factors such as EGR-1 and NEK11 are targets for SDC1 in the cell nucleus. 
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In the second study we aimed to discover more about the role of nuclear SDC1 through 
identifying its nuclear interactome in a mesothelioma cell line. Nuclear proteins associated with 
cell proliferation were found in the SDC1 precipitate, but also that SDC1 was related to proteins 
involved in RNA synthesis.  
The results suggest that the regulatory effect on cell proliferation, which we found in study one, 
is related to nuclear SDC1. Of the eight pathways, where SDC1 interacts with nuclear proteins, 
five were related to different aspects of RNA transcription and export. Two of these, mRNA 
surveillance and Spliceosome, are linked together through common members of the Exon 
junction complex (EJC). The EJC regulates translation, as well as mRNA surveillance and 
localization [192–194]. These results indicate that SDC1 might regulate the binding of EJC and 
mRNA, and play a role in the degradation of the mRNA through different mechanisms [192]. 
SDC1 was also found to interact with three EJC inner core factors, Y14, MAGOH and eIF4AIII. 
Two other interactors of SDC1were identified, EDC3 and EDC4 (enhancer of mRNA-decapping 
protein 3 and 4), which also affect mRNA degradation [195, 196]. Similar to the previously 
found effects on cell proliferation, both the up- and downregulation of SDC1 reduced the total 
cellular amount of RNA. In short, the protein networks which interact with nuclear SDC1 
regulate two main functions: cell proliferation and RNA transport and transcription 
modification. Decreasing or increasing SDC1 inhibit these functions in a regulatory manner. 
Among these proteins, EWSR1 and FUS were identified as co-precipitating with SDC1. A 
previous study has shown that MM is related to recurrent EWSR1/FUS fusions [197].  
In the third study we have shown that knockdown of SDC1 sensitizes A549 cells to TGF-1-
induced EMT. After knockdown of SDC1 E-cadherin was more repressed and N-cadherin more 
induced. Also, nuclear localization of Zeb1 was increased, suggesting a role for SDC1 in 
regulating the activity of core EMT transcription factors. This was obvious in the carcinoma cell 
line with its high basic production of SDC1, while no effect could be seen when modulating the 
SDC1 expression in the sarcomatous cells with their lower levels of SDC1. As recent research 
has identified Zeb1 as a suppressor of SDC1 in prostate cancer cell lines with EMT [198], there 
is possibly a feedback loop by which they inhibit the activity of each other. In B6FS 
fibrosarcoma cells, overexpression of SDC1 suppressed the levels of N-cadherin and vimentin, 
which are proteins related to a mesenchymal phenotype.  
Taken together, these studies show the different roles of SDC1 in the process of EMT and in 











Paper I: Molecular targets and signaling pathways regulated by nuclear translocation 
of syndecan-1 
➢ Proliferation and cell cycle are hampered by nuclear syndecan-1 (nSDC1) 
➢ These effects are regulated by multiple actors in related signaling pathways, where 
TGF-1 seems to play a central role 
➢ nSDC1 enhances expression of EGR1, NEK11, DOCK8 
➢ Activity of several other transcription factors such as NFκβ and E2F-1 is augmented 
by nSDC1 
➢ Network analysis shows overlap of biological processes in transcripts and proteins 
affected 
 
Paper II: Mapping the Interactome of the Nuclear Heparan Sulfate Proteoglycan 
Syndecan-1 in Mesothelioma Cells 
➢ The results suggest a previously unknown role for SDC1 in RNA biogenesis 
➢ SDC1 plays a role in various pathways, from cell proliferation to RNA synthesis and 
transport 
➢ This study is a first step towards discovering the role of nuclear SDC1 in normal and 
cancer cells of different origin 
 
Paper III: Regulation of epithelial-mesenchymal plasticity in tumor cells by syndecan-1 
➢ SDC1 knockdown sensitizes A549 cells to TGF-1-induced EMT 
➢ SDC1 plays a role in regulating the activity of core EMT transcription factors 
➢ Overexpression of SDC1 in B6FS cells leads to suppression of N-cadherin and 









7 FUTURE PERSPECTIVES  
The overall aim of this thesis was to study the role of SDC1 in malignancy, in particular its 
effect on EMT, and the functions of SDC1 nuclear transportation. 
Our results from the first study indicate that EGR-1, NEK11 and other transcription factors are 
SDC1 targets in the nucleus. However, it is not yet clear if they are direct targets or mediators of 
the effect of SDC1 in the nucleus. It might also be interesting to further study whether SDC1 
could be regulating the binding of EJC and mRNA and helping in the degradation of the mRNA. 
We know that EDC3 and EDC4 assist in mRNA decapping and degradation, but the exact 
process and the role of SDC1 is yet to be proved in vitro and/or in vivo.  
Our research indicates that SDC1 plays a role in various pathways, including cell proliferation 
and RNA synthesis and transport. However, the results are based on SDC1 interacting proteins 
in a single mesothelioma cell line, which makes it difficult to draw generalized conclusions    
about the SDC1 nuclear interactions in other cell types. Further research is needed to define the 
exact molecular mechanisms of nuclear SDC1 and its involvement in these pathways, as well as 
to study its possible importance in different types of cancer like MM.  
Previous studies have indicated SDC1 as a powerful suppressor of the TGF- pathway in 
mesothelioma. We have found that SDC1 is involved in regulating TGF-1-induced EMT, but 
more research is needed to fully investigate the molecular links in this process. It would also be 
interesting to further study the role of SDC1 in epithelial-mesenchymal plasticity during 
metastasis. 
Overall, the findings of this thesis may serve as a basis for further study of the function of SCD1 
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